WP
BPMC

Woodline Partners’s Blueprint Medicines BPMC Stock Holding History

Woodline Partners’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-531,880
Closed -$68.2M – 895
2025
Q2 		$68.2M Sell
531,880
-8,858
-2% -$920K 0.36% 55
2025
Q1 		$47.9M Buy
540,738
+546
+0.1% +$53.3K 0.31% 92
2024
Q4 		$47.1M Buy
540,192
+86,614
+19% +$7.93M 0.32% 84
2024
Q3 		$42M Sell
453,578
-426,569
-48% -$42.4M 0.35% 87
2024
Q2 		$94.9M Buy
880,147
+52,974
+6% +$5.3M 0.91% 17
2024
Q1 		$78.5M Buy
827,173
+12,700
+2% +$1.09M 0.72% 23
2023
Q4 		$75.1M Buy
814,473
+212,446
+35% +$13.8M 0.82% 25
2023
Q3 		$30.2M Buy
602,027
+310,665
+107% +$16.6M 0.35% 71
2023
Q2 		$18.4M Buy
291,362
+185,985
+176% +$10.1M 0.22% 142
2023
Q1 		$4.74M Sell
105,377
-135,317
-56% -$6.1M 0.06% 301
2022
Q4 		$10.5M Buy
240,694
+147,307
+158% +$7.06M 0.14% 199
2022
Q3 		$6.15M Sell
93,387
-22,700
-20% -$1.46M 0.09% 261
2022
Q2 		$5.86M Buy
116,087
+91,214
+367% +$5.34M 0.09% 239
2022
Q1 		$1.59M Sell
24,873
-37,182
-60% -$2.67M 0.03% 411
2021
Q4 		$6.65M Sell
62,055
-109,980
-64% -$11.5M 0.1% 249
2021
Q3 		$17.7M Buy
172,035
+114,979
+202% +$10.7M 0.29% 99
2021
Q2 		$5.02M Sell
57,056
-31,850
-36% -$2.92M 0.09% 216
2021
Q1 		$8.64M Buy
+88,906
New +$8.88M 0.19% 138

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Woodline Partners's BPMC Position: Q3 2025 in Review

Woodline Partners sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 531,880 shares — an estimated $68.2M sold.

Woodline Partners first reported a position in BPMC in Q1 2021 and held it in 18 quarters. The position peaked at $94.9M in Q2 2024. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Woodline Partners reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Woodline Partners sold 531,880 Blueprint Medicines shares in Q3 2025, an estimated $68.2M.
  • Woodline Partners first reported a position in Blueprint Medicines in Q1 2021 and held it in 18 quarters.
  • Woodline Partners's Blueprint Medicines position peaked at $94.9M in Q2 2024.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Woodline Partners's 13F filing for Q3 2025, filed 14 Nov 2025.